開示情報 > RaQualia Announces Top-Line Results of Phase III clinical trial of Ziprasidone Conducted by Meiji Seika Pharma in Patients with Schizophrenia in Japan

RaQualia Announces Top-Line Results of Phase III clinical trial of Ziprasidone Conducted by Meiji Seika Pharma in Patients with Schizophrenia in Japan

RaQualia Announces Top-Line Results of Phase III clinical trial of Ziprasidone Conducted by Meiji Seika Pharma in Patients with Schizophrenia in Japan

開示者 【45790】ラクオリア創薬株式会社
文書名 RaQualia Announces Top-Line Results of Phase III clinical trial of Ziprasidone Conducted by Meiji Seika Pharma in Patients with Schizophrenia in Japan  
PDF/XBRL [別ウインドウでPDFを開く]
開示日時 2019/09/06 チャネル/カテゴリ 東京証券取引所 /その他
ノート ログインするとIR文書にメモを入力して管理することができます
右上のログインメニューからログインしてください。


開示情報 > RaQualia Announces Top-Line Results of Phase III clinical trial of Ziprasidone Conducted by Meiji Seika Pharma in Patients with Schizophrenia in Japan